{"id":"W2529895151","doi":"10.1182/blood.v118.21.269.269","title":"Randomized Phase II Trial Comparing GA101 (Obinutuzumab) with Rituximab in Patients with Relapsed CD20 Indolent B-Cell Non-Hodgkin Lymphoma: Preliminary Analysis of the GAUSS Study","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Rituximab; Medicine; Obinutuzumab; Internal medicine; Follicular lymphoma; Clinical endpoint; Regimen; Population; CD20; Neutropenia; Phases of clinical research; Clinical trial; Oncology; Lymphoma; Surgery; Gastroenterology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high","status":"direct model label, unvalidated"}],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001174399,0.0003684107,0.002019451,0.0005872968,0.0001283111,0.00001619526,0.0004403154,0.0001205781,0.00006490781],"category_scores_gemma":[0.0001732683,0.0002063448,0.0003250311,0.0017734,0.0003397145,0.00009725906,0.0003146762,0.0002954343,0.000005129028],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00203719,"about_ca_system_score_gemma":0.003390331,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002565945,"about_ca_topic_score_gemma":0.0003675665,"domain_scores_codex":[0.9960575,0.0005295386,0.0009573181,0.0006123421,0.001305889,0.0005374589],"domain_scores_gemma":[0.9975836,0.0002951133,0.0004791043,0.001207489,0.0002539377,0.0001807182],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8707798,0.08776242,0.03000628,0.00009826916,0.003557401,0.0001471344,0.00735171,0.00005646429,0.00002016823,0.0000023688,0.00001742181,0.0002005339],"study_design_scores_gemma":[0.941757,0.01592141,0.02476476,0.0002360749,0.009657018,0.000008753749,0.0006816949,0.005064511,0.001674154,0.000002036062,0.000002158945,0.0002304262],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9917265,0.00007850359,0.00002589601,0.000008304746,0.00006570636,0.006683353,0.00001171667,0.00002982239,0.001370266],"genre_scores_gemma":[0.999081,0.000006032014,0.000227521,0.00002255049,0.00003827042,0.0003786274,0.00004175339,0.00005044132,0.0001538497],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07184102,"threshold_uncertainty_score":0.8414497,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02219480741726867,"score_gpt":0.2705518785369483,"score_spread":0.2483570711196797,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}